[go: up one dir, main page]

PE20060466A1 - Proceso para preparar bisulfato de atazanavir y formas cristalinas del mismo - Google Patents

Proceso para preparar bisulfato de atazanavir y formas cristalinas del mismo

Info

Publication number
PE20060466A1
PE20060466A1 PE2005000500A PE2005000500A PE20060466A1 PE 20060466 A1 PE20060466 A1 PE 20060466A1 PE 2005000500 A PE2005000500 A PE 2005000500A PE 2005000500 A PE2005000500 A PE 2005000500A PE 20060466 A1 PE20060466 A1 PE 20060466A1
Authority
PE
Peru
Prior art keywords
atazanavir
bisulphate
crystals
prepare
bisulfate
Prior art date
Application number
PE2005000500A
Other languages
English (en)
Inventor
Soojin Kim
Bruce T Lotz
Mary F Malley
Martha Davidovich
Sushil K Srivastava
Jack Z Gougoutas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060466(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060466A1 publication Critical patent/PE20060466A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN PROCESO PARA PREPARAR BISULFATO DE ATAZANAVIR EN FORMA DE CRISTALES DE FORMA A, DONDE DICHO PROCESO COMPRENDE HACER REACCIONAR UNA SOLUCION DE BASE LIBRE DE ATAZANAVIR EN UN SOLVENTE ORGANICO, EN LA CUAL LA SAL DE BISULFATO DE ATAZANAVIR ES SOLUBLE, CON UNA PRIMERA PORCION DE ACIDO SULFURICO CONCENTRADO EN UNA CANTIDAD PARA REACCIONAR CON MENOS DE 15% EN PESO DE LA BASE LIBRE DE ATAZANAVIR, AGREGAR SEMILLAS DE LOS CRISTALES DE FORMA A DE BISULFATO DE ATAZANAVIR A LA MEZCLA DE REACCION, COMO CRISTALES DE FORMA DE BISULFATO DE ATAZANAVIR, AGREGAR ACIDO SULFURICO CONCENTRADO ADICIONAL EN ETAPAS MULTIPLES PARA EFECTUAR LA FORMACION DE CRISTALES DE BISULFATO DE ATAZANAVIR, Y SECAR EL BISULFATO DE ATAZANAVIR PARA FORMAR LOS CRISTALES DE FORMA A. TAMBIEN SE REFIERE A UN PROCESO PARA PREPARAR BISULFATO DE ATAZANAVIR COMO MATERIAL DE CONFIGURACION C Y A UNA NUEVA FORMA DE BISULFATO DE ATAZANAVIR, LA CUAL ES LA FORMA E3. DICHO BISULFATO DE ATAZANAVIR ES UN INHIBIDOR DE LA PROTEASA DEL VIH
PE2005000500A 2004-05-04 2005-05-04 Proceso para preparar bisulfato de atazanavir y formas cristalinas del mismo PE20060466A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60753304P 2004-09-07 2004-09-07

Publications (1)

Publication Number Publication Date
PE20060466A1 true PE20060466A1 (es) 2006-06-01

Family

ID=35320785

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005000500A PE20060466A1 (es) 2004-05-04 2005-05-04 Proceso para preparar bisulfato de atazanavir y formas cristalinas del mismo
PE2005000498A PE20060216A1 (es) 2004-05-04 2005-05-04 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005000498A PE20060216A1 (es) 2004-05-04 2005-05-04 Proceso que emplea cristalizacion controlada en la formacion de cristales de un producto farmaceutico

Country Status (8)

Country Link
US (1) US20050256314A1 (es)
EP (1) EP1758664A4 (es)
AR (2) AR048937A1 (es)
CL (1) CL2011003144A1 (es)
PE (2) PE20060466A1 (es)
RU (1) RU2385325C2 (es)
TW (3) TWI518072B (es)
WO (1) WO2005108380A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US20100204470A1 (en) * 2006-06-27 2010-08-12 Sandoz Ag method for salt preparation
CN101778625A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
KR20100033377A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
ES2360336T3 (es) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
NZ609807A (en) * 2007-07-10 2014-07-25 Boehringer Ingelheim Int Optical filling control of pharmaceutical capsules in capsule filling machines
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940998A (en) * 1953-10-15 1960-06-14 Ajinomoto Kk Process for resolution of racemic glutamic acid and salts thereof
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
CN1161341C (zh) * 1999-03-22 2004-08-11 布里斯托尔-迈尔斯斯奎布公司 cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
TWI236930B (en) * 2000-05-26 2005-08-01 Pfizer Prod Inc Reactive crystallization method to improve particle size
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method

Also Published As

Publication number Publication date
AR049268A1 (es) 2006-07-12
TWI518072B (zh) 2016-01-21
US20050256314A1 (en) 2005-11-17
EP1758664A4 (en) 2010-12-22
TW201427949A (zh) 2014-07-16
WO2005108380A3 (en) 2006-08-24
TW200600498A (en) 2006-01-01
TW200606142A (en) 2006-02-16
WO2005108380A2 (en) 2005-11-17
RU2385325C2 (ru) 2010-03-27
PE20060216A1 (es) 2006-03-17
CL2011003144A1 (es) 2012-04-13
RU2006142768A (ru) 2008-06-10
AR048937A1 (es) 2006-06-14
TWI445697B (zh) 2014-07-21
EP1758664A2 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
AR099594A2 (es) Proceso para preparar bisulfato de atazanavir y otras formas
PE20060466A1 (es) Proceso para preparar bisulfato de atazanavir y formas cristalinas del mismo
JP2013539448A5 (es)
CY1116919T1 (el) Διαδικασια παρασκευης οξινης θειικης αταζαναβιρης και καινοτομων μορφων
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
AR076974A1 (es) Metodo para sintetizar pirfenidona
ATE544726T1 (de) Herstellung von nanostrukturen
AR065775A1 (es) Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos
AR074637A1 (es) Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos
UY32243A (es) Proceso para la fabricacion de bromuros de 3-piridilmetil amonio sustituidos
BR112012019183A2 (pt) processo para a fabricação de um epóxido, e, dispositivo para realizar o processo
MX385690B (es) Método novedoso para producir 4,5-dihidroisoxazol 5,5-disustituido.
AR094054A1 (es) 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
AR109729A1 (es) Método para producir la forma cristalina de modificación a de calcobutrol
AR116423A1 (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma
AR090609A1 (es) Proceso de produccion de xilenos mediante la integracion de la metilacion con la transalquilacion
AR079575A1 (es) Procedimiento para la purificacion de pirazoles
PE20110163A1 (es) Proceso para la preparacion de derivados de pirimidina sustituidos
PE20060650A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
CL2019002795A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano.
AR087090A1 (es) Proceso para la preparacion de aminonitrilo y diamina, y los dispositivos correspondientes
RU2008136365A (ru) Способ получения о-метил-n-нитроизомочевины

Legal Events

Date Code Title Description
FC Refusal